Sphingomyelin liposomes containing porphyrin-phospholipid for irinotecan chemophototherapy

Theranostics

Volumn 6, Issue 13, 2016, Pages 2329-2336

  Carter, Kevin A ^a   Luo, Dandan ^a   Razi, Aida ^b   Geng, Jumin ^a   Shao, Shuai ^a   Ortega, Joaquin ^b   Lovell, Jonathan F ^a  

^a University at Buffalo The State University of New York   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Chemophototherapy; Irinotecan; Liposomes

Indexed keywords

CHOLESTEROL; IRINOTECAN; LIPID; LIPOSOME; PHOSPHOLIPID; PORPHYRIN; SPHINGOMYELIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISEASE ERADICATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG RELEASE; DRUG STABILITY; FEMALE; IN VIVO STUDY; IRRADIATION; LIGHT EXPOSURE; LIPID COMPOSITION; MICROSCOPY; MOUSE; NONHUMAN; PHOTOCHEMOTHERAPY; RADIATION RESPONSE; SUBCUTANEOUS TISSUE TUMOR; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DISEASE MODEL; INFRARED RADIATION; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HETEROGRAFTS; INFRARED RAYS; LIPOSOMES; MICE; PANCREATIC NEOPLASMS; PHOSPHOLIPIDS; PORPHYRINS; SPHINGOMYELINS; TREATMENT OUTCOME;

EID: 84999864908     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.15701     Document Type: Article

References (59)

1. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005;4:145-60.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007;2:751-60.
3. Wang AZ, Langer R, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. Annu. Rev. Med. 2012;63:185-98.
4. Allen TM, Cullis PR. Drug Delivery Systems: Entering the Mainstream. Science. 2004;303:1818-22.
5. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev. 2011;63:161-9.
6. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011;63:136-51.
7. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011;63:131-5.
8. Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J. Controlled Release. 2012;164:138-44.
9. Barenholz Y. Doxil®-The first FDA-approved nano-drug: Lessons learned. J. Controlled Release. 2012;160:117-34.
10. Manzoor AA, Lindner LH, Landon CD, Park J-Y, Simnick AJ, Dreher MR, et al. Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release to Improve Drug Penetration into Tumors. Cancer Res. 2012;72:5566-75.
11. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology. Cancer Res. 2013;73:2412-7.
12. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010;7:653-64.
13. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014;66:2-25.
14. Mills JK, Needham D. Targeted drug delivery. Expert Opin. Ther. Pat. 1999;9:1499-513.
15. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine Nanotechnol. Biol. Med. 2005;1:193-212.
16. Freeman AI, Mayhew E. Targeted drug delivery. Cancer. 1986;58:573-83.
17. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Controlled Release. 2008;126:187-204.
18. Luo D, Carter KA, Lovell JF. Nanomedical engineering: shaping future nanomedicines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015;7:169-88.
19. You J, Zhang G, Li C. Exceptionally High Payload of Doxorubicin in Hollow Gold Nanospheres for Near-Infrared Light-Triggered Drug Release. ACS Nano. 2010;4:1033-41.
20. Timko BP, Kohane DS. Prospects for near-infrared technology in remotely triggered drug delivery. Expert Opin. Drug Deliv. 2014;11:1681-5.
21. Araki T, Ogawara K, Suzuki H, Kawai R, Watanabe T, Ono T, et al. Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature. J. Controlled Release. 2015;200:106-14.
22. Fomina N, Sankaranarayanan J, Almutairi A. Photochemical mechanisms of light-triggered release from nanocarriers. Adv. Drug Deliv. Rev. 2012;64:1005-20.
23. Zhen Z, Tang W, Chen H, Lin X, Todd T, Wang G, et al. RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors. ACS Nano. 2013;7:4830-7.
24. He C, Liu D, Lin W. Self-Assembled Core-Shell Nanoparticles for Combined Chemotherapy and Photodynamic Therapy of Resistant Head and Neck Cancers. ACS Nano. 2015;9:991-1003.
25. Spring BQ, Sears RB, Zheng LZ, Mai Z, Watanabe R, Sherwood ME, et al. A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat. Nanotechnol. 2016;11:378-87.
26. Yen H-C, Cabral H, Mi P, Toh K, Matsumoto Y, Liu X, et al. Light-Induced Cytosolic Activation of Reduction-Sensitive Camptothecin-Loaded Polymeric Micelles for Spatiotemporally Controlled in Vivo Chemotherapy. ACS Nano. 2014;8:11591-602.
27. Luo D, Carter KA, Miranda D, Lovell JF. Chemophototherapy: An Emerging Treatment Option for Solid Tumors. Adv. Sci. 2016.
28. Huang H, Song W, Rieffel J, Lovell JF. Emerging applications of porphyrins in photomedicine. Front. Phys. 2015;3:23.
29. Zhang Y, Lovell JF. Porphyrins as theranostic agents from prehistoric to modern times. Theranostics. 2012;2:905-15.
30. Zhang Y, Lovell JF. Recent applications of phthalocyanines and naphthalocyanines for imaging and therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016.
31. Carter KA, Shao S, Hoopes MI, Luo D, Ahsan B, Grigoryants VM, et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat. Commun. 2014; 5:3546.
32. Luo D, Carter KA, Razi A, Geng J, Shao S, Lin C, et al. Porphyrin-phospholipid liposomes with tunable leakiness. J. Controlled Release. 2015;220:484-94.
33. Luo D, Carter KA, Razi A, Geng J, Shao S, Giraldo D, et al. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Biomaterials. 2016;75:193-202.
34. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat. Mater. 2011;10:324-32.
35. Carter KA, Wang S, Geng J, Luo D, Shao S, Lovell JF. Metal Chelation Modulates Phototherapeutic Properties of Mitoxantrone-Loaded Porphyrin-Phospholipid Liposomes. Mol. Pharm. 2016;13:420-7.
36. Shao S, Geng J, Ah Yi H, Gogia S, Neelamegham S, Jacobs A, et al. Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens. Nat. Chem. 2015;7:438-46.
37. Kress J, Rohrbach DJ, Carter KA, Luo D, Shao S, Lele S, et al. Quantitative imaging of light-triggered doxorubicin release. Biomed. Opt. Express. 2015;6:3546-55.
38. Rieffel J, Chen F, Kim J, Chen G, Shao W, Shao S, et al. Hexamodal Imaging with Porphyrin-Phospholipid-Coated Upconversion Nanoparticles. Adv. Mater. 2015;27:1785-90.
39. Luo D, Li N, Carter KA, Lin C, Geng J, Shao S, et al. Rapid Light-Triggered Drug Release in Liposomes Containing Small Amounts of Unsaturated and Porphyrin-Phospholipids. Small. 2016;12:3039-47.
40. Lovell JF, Jin CS, Huynh E, MacDonald TD, Cao W, Zheng G. Enzymatic Regioselection for the Synthesis and Biodegradation of Porphysome Nanovesicles. Angew. Chem. Int. Ed. 2012;51:2429-33.
41. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim. Biophys. Acta BBA-Biomembr. 2006;1758:1633-40.
42. Lasic DD, Frederik PM, Stuart MCA, Barenholz Y, McIntosh TJ. Gelation of liposome interior A novel method for drug encapsulation. FEBS Lett. 1992;312:255-8.
43. Andriyanov AV, Koren E, Barenholz Y, Goldberg SN. Therapeutic Efficacy of Combining PEGylated Liposomal Doxorubicin and Radiofrequency (RF) Ablation: Comparison between Slow-Drug-Releasing, Non-Thermosensitive and Fast-Drug-Releasing, Thermosensitive Nano-Liposomes. PLoS ONE. 2014;9:e92555.
44. Chou T-H, Chen S-C, Chu I-M. Effect of Composition on the stability of liposomal irinotecan prepared by a pH gradient method. J. Biosci. Bioeng. 2003;95:405-8.
45. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms E-M, Harasym N, et al. Liposomal Irinotecan Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer. Clin. Cancer Res. 2004;10:6638-49.
46. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy. Cancer Res. 2006;66:3271-7.
47. Mathijssen RHJ, Alphen RJ van, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin. Cancer Res. 2001;7:2182-94.
48. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine. 2012;7:49-60.
49. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, et al. Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation. Pharm. Res. 2006;23:2799-808.
50. Wei H, Song J, Li H, Li Y, Zhu S, Zhou X, et al. Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation. Asian J. Pharm. Sci. 2013;8:303-11.
51. Li X, Mooney P, Zheng S, Booth CR, Braunfeld MB, Gubbens S, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat. Methods. 2013;10:584-90.
52. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer. 1995;72:896-904.
53. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000;60:3389-93.
54. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 2003;63:8126-31.
55. Sano K, Nakajima T, Choyke PL, Kobayashi H. Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors. ACS Nano. 2013;7:717-24.
56. Zhen Z, Tang W, Chuang Y-J, Todd T, Zhang W, Lin X, et al. Tumor Vasculature Targeted Photodynamic Therapy for Enhanced Delivery of Nanoparticles. ACS Nano. 2014;8:6004-13.
57. Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal RD. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int. J. Oncol. 2002;20:379-84.
58. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-Oncol. 2007;9:393-403.
59. Hattori Y, Shi L, Ding W, Koga K, Kawano K, Hakoshima M, et al. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J. Controlled Release. 2009;136:30-7.